UC Davis Researchers Develop Light-Driven Method to Create Non-Hallucinogenic Psychedelic-Like Compounds
Similar Articles
New Light-Driven Method Creates Strained Molecules for Drug Development
Researchers Identify Enzymes for Production of Rare Plant Compound Mitraphylline
Researchers Identify New Enzyme Target That Reduces Alzheimer's Plaques in Lab Studies
Amino Acid Supplement Boosts mRNA Delivery and Gene Editing Efficiency
Scientists Discover Rare Medicinal Compounds in Cannabis Leaves
Scientists at UC Davis have created new molecules that activate key serotonin receptors linked to brain cell growth, using a light-driven process on amino acids. In mouse tests, the most potent compound showed no signs of hallucinogenic effects. The work, published in the Journal of the American Chemical Society, represents a step toward potential neurotherapeutics.
Facts First
- Researchers developed a light-driven technique to convert amino acids into compounds that activate serotonin 5-HT2A receptors.
- The strongest compound, D5, acted as a full agonist of the 5-HT2A receptor but did not produce hallucinogenic-like head twitch responses in mice.
- The findings were published in the Journal of the American Chemical Society.
- The research was funded by grants from the National Institutes of Health and the Source Research Foundation.
What Happened
Researchers at the University of California, Davis (UC Davis) developed a new method to create compounds that behave similarly to psychedelics in the brain. They combined amino acids with tryptamine and exposed the resulting molecules to ultraviolet (UV) light to trigger chemical changes. Using computer modeling, they evaluated 100 of these new compounds for interaction with the brain's serotonin 5-HT2A receptor, which is associated with brain cell growth. Five compounds were selected for detailed lab testing, with activity levels ranging from 61% to 93%. The strongest performer, named D5, acted as a full agonist of the receptor but, in mouse experiments, D5 did not produce head twitch responses, which are indicators of hallucinogenic-like effects.
Why this Matters to You
This research may lead to new treatments for mental health conditions like depression and anxiety without the hallucinogenic side effects associated with classic psychedelics. If successful, this could provide you or someone you know with more therapeutic options that target brain plasticity in a potentially safer way. The use of a light-driven process and common amino acids suggests the method could be efficient and scalable for future drug development.
What's Next
The research team... will likely conduct further studies to understand the therapeutic potential of these compounds. The absence of hallucinogenic effects in mice suggests these molecules could be promising candidates for developing non-hallucinogenic neurotherapeutics. Further research may explore their efficacy in models of specific neurological or psychiatric disorders.